Table 2.
Cerebrovascular and cardiorespiratory variables prior to and for 90-min following Placebo or Indo administration.
| Placebo | Indo | |||
|---|---|---|---|---|
| Men | Women | Men | Women | |
| MABP (mmHg)1,2 | ||||
| Baseline | 88 ± 1 | 86 ± 1 | 90 ± 2 | 86 ± 2 |
| 30 min | 90 ± 2 | 87 ± 1 | 94 ± 2 | 90 ± 1 |
| 60 min | 89 ± 2 | 87 ± 2 | 92 ± 2 | 93 ± 1 |
| 90 min | 89 ± 1 | 86 ± 1 | 94 ± 2 | 91 ± 1 |
| PETco2 (mmHg)1,2 | ||||
| Baseline | 38 ± 1 | 36 ± 1 | 38 ± 1 | 37 ± 1 |
| 30 min | 39 ± 0 | 37 ± 1 | 38 ± 0 | 37 ± 0 |
| 60 min | 39 ± 0 | 38 ± 1 | 38 ± 0 | 37 ± 1 |
| 90 min | 38 ± 1 | 38 ± 1 | 38 ± 1 | 37 ± 1 |
| SpO2 (%) | ||||
| Baseline | 99 ± 0 | 99 ± 0 | 99 ± 0 | 99 ± 0 |
| 30 min | 99 ± 0 | 99 ± 0 | 99 ± 0 | 99 ± 0 |
| 60 min | 99 ± 0 | 99 ± 0 | 99 ± 0 | 99 ± 0 |
| 90 min | 99 ± 0 | 99 ± 0 | 99 ± 0 | 99 ± 0 |
| MCAv (cm sec−1)1,2,3 | ||||
| Baseline | 69 ± 3 | 75 ± 3 | 70 ± 3 | 74 ± 3 |
| 30 min | 71 ± 3 | 78 ± 3 | 57 ± 3 | 60 ± 3 |
| 60 min | 72 ± 3 | 78 ± 4 | 50 ± 3 | 52 ± 2 |
| 90 min | 71 ± 3 | 79 ± 3 | 47 ± 3 | 52 ± 2 |
| ΔMCAv | ||||
| 90 min | 1 ± 1 | 4 ± 2 | 22 ± 2 | 23 ± 2 |
| % ΔMCAv | ||||
| 90 min | 2 ± 2 | 6 ± 3 | 32 ± 3 | 30 ± 2 |
| CVCi (cm sec−1 mmHg−1)1,2,3 | ||||
| Baseline | 79 ± 3 | 88 ± 4 | 78 ± 4 | 87 ± 3 |
| 30 min | 79 ± 3 | 90 ± 4 | 61 ± 4 | 67 ± 3 |
| 60 min | 81 ± 3 | 91 ± 4 | 54 ± 3 | 57 ± 3 |
| 90 min | 80 ± 3 | 92 ± 4 | 50 ± 3 | 57 ± 2 |
| Δ CVCi | ||||
| 90 min | 1 ± 2 | 4 ± 3 | 28 ± 3 | 30 ± 3 |
| % Δ CVCi | ||||
| 90 min | 1 ± 2 | 6 ± 4 | 35 ± 3 | 34 ± 3 |
Values are presented as mean ± SE. Indo, indomethacin; MABP, mean arterial blood pressure; PETCO2, end-tidal carbon dioxide; SPO2, pulse oximetry oxygen saturation; MCAv, middle cerebral artery velocity; ΔMCAv, absolute change in MCAv; %ΔMCAv, relative change in MCAv; CVCi, cerebrovascular conductance index; ΔCVCi, absolute change in CVCi; %ΔCVCi, relative change in CVCi.
1
Placebo main effect of group.
2
Indo main effect of group.
3
Indo main effect of time; P < 0.05.